Neurological disorders Archives

alzheimers disease phase iii UK 1 e1557338331863

News and Trends 24 Mar 2020

Eli Lilly Sweetens AC Immune Alzheimer’s Treatment Deal by €38M

A deal between Swiss biotech AC Immune and Eli Lilly to develop an oral Alzheimer’s disease drug has increased in worth by €38M with a new milestone payment. AC Immune and Eli Lilly modified a deal signed in late 2018 to co-develop a small molecule treatment to slow the progression of Alzheimer’s disease. Specifically, the […]

March 24, 2020 - 3 minutesmins - By Jonathan Smith

multiple sclerosis neuron sheath medday Pharma

News and Trends 11 Mar 2020

Phase III Fail for MedDay’s Multiple Sclerosis Treatment

A drug developed by the French company MedDay Pharmaceuticals has failed to treat progressive forms of multiple sclerosis in a phase III trial. The 642 patients recruited into the trial received either a placebo or a high dose of pharmaceutical-grade Biotin, also known as vitamin B₇. The patients had various forms of the autoimmune condition […]

March 11, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 27 Feb 2020

Scientists Connect Brain Cells to Machines Over the Internet

An international group of researchers has set up a brain-machine interface between cultured nerve cells and electronic chips linked over the internet, which could lead to the development of AI implants for treating neurological disorders. As described in a study published in Nature Scientific Reports, the team set up a system where cultured rat nerve […]

February 27, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Feb 2020

EU Project Set up to Fight Alzheimer’s Disease with Lasers

A project has launched with a €3.6M grant to treat neurological conditions such as Alzheimer’s and Huntington’s disease by making brain cells controllable with red light. There are currently no treatments approved that can slow the progression of neurodegenerative conditions, including Alzheimer’s and Huntington’s disease. Treatments approved to alleviate the symptoms only help a small […]

February 7, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 4 Feb 2020

Swiss Biotech Raises €16M to Treat Autism Spectrum Disorder

Stalicla has bagged €16.3M in a Series A round to test drugs repurposed using AI for the treatment of autism spectrum disorder in phase I. The round consists of a recent €7M (CHF 7.7M) closing and an initial first tranche of €9.3M (CHF 10M) raised last year. The investors in the latest closing were not […]

February 4, 2020 - 2 minutesmins - By Jonathan Smith

In Depth 9 Dec 2019

As Big Pharma Abandons Neuroscience, Can Biotech Provide Answers?

With big pharma exiting the neurology space in droves, biotech innovation might be the key to bring about a much-needed shift. At the Bio-Europe conference in Hamburg last month, experts weighed in on the challenges and future of neuroscience. Over the last decade, big pharma has become disillusioned with neuroscience research. Eli Lilly, Amgen, Pfizer, […]

December 9, 2019 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Sep 2019

Orchard’s Gene Therapy Improves Children’s Motor Ability

Orchard Therapeutics’ gene therapy for metachromatic leukodystrophy (MLD) resulted in motor ability improvements more than six times over the target endpoint, according to data released at a recent symposium. “Metachromatic leukodystrophy is a rare disease that affects the brain,” explained Mark Rothera, CEO of Orchard Therapeutics. “Kids born with MLD lose motor function very fast […]

September 5, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

pure biologics wroclaw devics disease 1 1

Startup Scout 31 May 2019

This Biotech Treats a Neurological Autoimmune Disorder Using DNA

We’re jumping into Poland this week. Pure Biologics is a biotech based in Wrocław developing DNA molecules that could treat the incurable neurological condition Devic’s disease with fewer side effects than existing treatments. Mission: To develop a treatment that makes an existing treatment for Devic’s disease, plasmapheresis, more targeted and with fewer side effects than […]

May 31, 2019 - 4 minutesmins - By Jonathan Smith

polyneuron anti mag peripheral neuropathy autoimmune disease nerve

News and Trends 28 Mar 2019

Swiss Biotech Raises €20M to Develop Decoy Drugs in Autoimmune Disease

The biotech Polyneuron has raised a Series A round of €20.1M (CHF 22.5M) to start human testing with a treatment for a rare autoimmune disease. Based in Basel, Polyneuron is developing drugs to treat anti-MAG peripheral neuropathy. This debilitating disease is caused by the immune system producing autoantibodies that attack nerve support cells, which stops […]

March 28, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 21 Feb 2018

Early Autism Diagnosis Could be Possible With New Blood and Urine Tests

The detection of damaged proteins in blood and urine tests could help to diagnose autism quicker so that children can be given appropriate treatment. Researchers at the University of Warwick have developed new blood and urine tests that detect damaged proteins, which are associated with autism spectrum disorders. The study, published in Molecular Autism, explains how […]

February 21, 2018 - 3 minutesmins - By Alex Dale

Interview 9 Nov 2017

Meet the Spin-Out Queen Taking on Neurological Diseases

Mary Kerr, CEO of NeRRe and Managing Director of KanDy, told us how its approaches could change the face of therapies for neuronal hypersensitivity and women’s health indications. Mary Kerr’s career has taken her through the rigorous world of big pharma, which she says gave her “the skillset… the development, the exposure and the opportunity to work […]

November 9, 2017 - 4 minutesmins - By Alex Dale

Theranexus IPO CNS Narcolepsy Parkinsons Alzheimers

News and Trends 30 Oct 2017

French Biotech Closes €19M IPO to Treat Narcolepsy and Alzheimer’s

Theranexus debuts on Euronext Paris raising €19.6M that will support the development of its pipeline of CNS drugs for narcolepsy, Parkinson’s, Alzheimer’s and neuropathic pain. Theranexus, based in Lyon, starts trading on Euronext Paris today. The company starts off with a market cap of €47.5M after closing a €19.6M IPO. With the money raised, the company […]

October 30, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us